Effect of synthetic corticosteroids on vascular reactivity in the human forearm

Clinical and Experimental Hypertension

Volumn 28, Issue 8, 2006, Pages 707-718

  Mangos, George J ^a   Walker, Brian R ^b   Williamson, Paula A ^a,c   Whitworth, Judith A ^c   Kelly, John J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c Australian National University   (Australia)

Author keywords

Cortisol; Dexamethasone; Endothelium; Fludrocortisone; Hypertension

Indexed keywords

ACETYLCHOLINE; CORTICOSTEROID; CORTICOSTEROID RECEPTOR; DEXAMETHASONE; FLUDROCORTISONE; FLUDROCORTISONE ACETATE; HYDROCORTISONE; N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE; PLACEBO;

ARTICLE; BLOOD CELL COUNT; BLOOD CHEMISTRY; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL REACTIVITY; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; FOREARM BLOOD FLOW; HUMAN; HUMAN EXPERIMENT; MALE; METABOLIC PARAMETERS; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; RECEPTOR UPREGULATION; STATISTICAL ANALYSIS; VASODILATATION; VOLUNTEER;

ACETYLCHOLINE; ADRENAL CORTEX HORMONES; ADULT; BLOOD PRESSURE; BLOOD VESSELS; DEXAMETHASONE; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FLUDROCORTISONE; FOREARM; HUMANS; MALE; NITRIC OXIDE SYNTHASE; OMEGA-N-METHYLARGININE; RECEPTORS, STEROID; VASODILATION;

EID: 33751581221     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.1080/10641960601013674     Document Type: Article

References (36)

1. Whitworth JA, Mangos GJ, Kelly JJ. Cushing, cortisol, and cardiovascular disease. Hypertension 2000; 36:912-916.
2. Mangos GJ, Kelly JJ, Whitworth JA. Cortisol and essential hypertension. Kidney 2000; 9:47-50.
3. Williamson PM, Kelly JJ, Whitworth JA. Dose-response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans. J Hypertens 1996;14:S37-S41.
4. Connell JM, Whitworth JA, Davies DL, Richards AM, Fraser R. Haemodynamic, hormonal and renal effects of adrenocorticotrophic hormone in sodium-restricted man. J Hypertens 1988;6:17-23.
5. Sudhir K, Jennings GL, Esler MD, Korner PI, Blombery PA, Lambert GW, Scoggins B, Whitworth JA. Hydrocortisone-induced hypertension in humans: pressor responsiveness and sympathetic function. Hypertension 1989; 13:416-421.
6. Tam ST, Kelly JJ, Williamson PM, Whitworth JA. Reflex sympathetic function in cortisol induced hypertension in humans. Clin Exp Hypertens 1996; 19:479-493.
7. Connell JM, Whitworth JA, Davies DL, Lever AF, Richards AM, Fraser R. Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man. J Hypertens 1987; 5:425-433.
8. Lou YK, Wen C, Li M, Adams DJ, Wang MX, Yang F, Morris BJ, Whitworth JA. Decreased renal expression of nitric oxide synthase isoforms in adrenocorticotropin-induced and corticosterone-induced hypertension. Hypertension 2001; 37:1164-1170.
9. Kelly JJ, Tam SH, Williamson PM, Lawson J, Whitworth JA. The nitric oxide system and cortisol-induced hypertension in humans. Clin Exp Pharmacol Physiol 1998; 25:945-946.
10. Mangos GJ, Walker B, Kelly JJ, Lawson JA, Webb DJ, Whitworth JA. Cortisol inhibits cholinergic vasodilation in the human forearm. Am J Hypertens 2000; 13:1155-1160.
11. Pirpiris M, Sudhir K, Yeung S, Jennings G, Whitworth JA. Pressor responsiveness in corticosteroid-induced hypertension in humans. Hypertension 1992; 19:567-574.
12. Whitworth JA, Saines D, Thatcher R. Differential blood pressure and metabolic effects of 9α fluorocortisol in man. Clin Exp Pharmacol Physiol 1993; 10:351-354.
13. Benjamin N, Calver A, Collier J, Robinson B, Vallance P, Webb D. Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension 1995; 25:918-923.
14. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; 997-1000.
15. Calver A, Collier J, Moncada S, Vallance P. Effect of local intra-arterial NG-monomethyl-Larginine in patients with hypertension: the nitric oxide dilator mechanism appears abnormal. J Hypertens 1992;10:1025-1031.
16. Field MJ, Stanton BA, Giebisch GH. Differential acute effects of aldosterone, dexamethason, and hyperkalemia on distal tubular potassium secretion in the rat kidney. J Clin Invest 1984;74:1792-1802.
17. Nakamoto H, Suzuki H, Kageyama Y, Ohishi, A., Murakami, M., Naitoh, M., Saruta, T. Characterization of alterations of hemodynamics and neuroedocrine hormones in dexamethasone induced hypertension in dogs. Clin Exp Hypertens 1991; 13:587-606.
18. Handa M, Kondo K, Suzuki H, Saruta T. Dexamethasone hypertension in rats: role of prostaglandins and pressor sensitivity to norepinephrine. Hypertension 1984; 6:T41.
19. Saruta T. Mechanism of glucocorticoid-induced hypertension. Hypertens Res 1996; 19:1-8.
20. Gerhard M, Roddy M, Creager SJ, Creager MA. Age progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans. Hypertension 1996; 27:849-853.
21. Wang J, Brown MA, Tam SH, Chan MC, Whitworth JA. Effects of diet on measurement of nitric oxide metabolites. Clin Exp Pharmacol Physiol 1987; 6:418-420.
22. Turner SW, Wen C, Li M, Whitworth JA. L-arginine prevents corticotropin-induced increases in blood pressure in the rat. Hypertension 1996; 27:184-189.
23. Li M, Fraser T, Wang J, Whitworth JA. Dexamethasone-induced hypertension in the rat: effects of l-arginine. Clin Exp Pharmacol Physiol 1997; 24:730-732.
24. Schmidt BM, Oehmer S, Delles C, Bratke R, Schneider MP, Klingbeil A, Fleischmann EH, Schmieder RE. Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension 2003, 42:156-160.
25. Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond). 2002; 103:425-431.
26. Alzamora R, Michea L, Marusic ET. Role of 11β-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries. Hypertension 2000; 35:1099-1104.
27. Bockman CS, Jeffries WB, Pettinger WA, Abel PW. Enhanced release of endothelium-derived relaxing factor in mineralocorticoid hypertension. Hypertension 1992; 20:304-313.
28. Vanhoutte PM. Endothelial dysfunction in hypertension. J Hypertens 1996; 14(Suppl.):S83-S93.
29. Hishikawa K, Nakaki T, Suzuki H, Kato R, Saruta T. Role of L-arginine nitric oxide pathway in hypertension. J Hypertens 1993; 11:639-645.
30. Panza JA, Quyyumi AA, Brush JEJ, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. NEJM 1990; 323:22-27.
31. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium derived nitric oxide in the abnormal endothelium-dependent vascular relaxation of patients with essential hypertension. Circulation 1993; 87:1468-1474.
32. Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Impaired endothelium-dependent vasodilation in patients with essential hypertension: evidence that the abnormality is not at the muscarinic receptor level. J Am Coll Cardiol 1994; 23:1610-1616.
33. Bruning TA, Chang PC, Kemme MJ, Vermeij P, Pfaffendorf M, Van ZP. Comparison of cholinergic vasodilator responses to acetylcholine and methacholin in the human forearm. Blood Press 1996; 5:333-341.
34. Martin K, Zipser R, Horton R. Effect of prostaglandin inhibition on the hypertensive action of sodium-retaining steroids. Hypertension 1981; 3:622-628.
35. Distler A, Philipp T. On the mechanism of mineralocorticoid induced hypertension: effects of 9 afluorohydrocortisone on haemodynamics in man. In: Central Nervous Control of Sodium Balance - Relations to the Renin-Angiotensin System. Stuttgart, Germany, George Thieme, 1976, 16.
36. Christy C, Hadoke PW, Paterson JM, Mullins JJ, Seckl JR, Walker BR. 11beta-hydroxysteroid dehydrogenase type 2 in mouse aorta: localization and influence on response to glucocorticoids. Hypertension. 2003; 42:580-587.